MA39304B1 - Formulations topiques d'héparine - Google Patents

Formulations topiques d'héparine

Info

Publication number
MA39304B1
MA39304B1 MA39304A MA39304A MA39304B1 MA 39304 B1 MA39304 B1 MA 39304B1 MA 39304 A MA39304 A MA 39304A MA 39304 A MA39304 A MA 39304A MA 39304 B1 MA39304 B1 MA 39304B1
Authority
MA
Morocco
Prior art keywords
heparin
topical formulations
present
relates
formulations
Prior art date
Application number
MA39304A
Other languages
English (en)
Other versions
MA39304A1 (fr
Inventor
K R Patel
M R Patel
A K Patel
Prakash J Shah
Original Assignee
Troikaa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52684592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39304(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Troikaa Pharmaceuticals Ltd filed Critical Troikaa Pharmaceuticals Ltd
Publication of MA39304A1 publication Critical patent/MA39304A1/fr
Publication of MA39304B1 publication Critical patent/MA39304B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des formulations topiques avancées de sels pharmaceutiquement acceptables d'héparine fournissant une meilleure pénétration transdermique. La présente invention concerne des formulations transparentes, non collantes liquides dans lesquelles le médicament est prêt pour l'absorption et qui sont appropriées pour l'administration sous la forme d'une solution ou d'une pulvérisation. Les formulations topiques de la présente invention ne forment pas de film de type feuilleté ou en gel sur la surface de la peau lors d'une application topique.
MA39304A 2014-02-10 2015-02-10 Formulations topiques d'héparine MA39304B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN475MU2014 2014-02-10
PCT/IB2015/050986 WO2015118512A1 (fr) 2014-02-10 2015-02-10 Formulations topiques d'héparine

Publications (2)

Publication Number Publication Date
MA39304A1 MA39304A1 (fr) 2018-01-31
MA39304B1 true MA39304B1 (fr) 2018-12-31

Family

ID=52684592

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39304A MA39304B1 (fr) 2014-02-10 2015-02-10 Formulations topiques d'héparine

Country Status (25)

Country Link
US (1) US9861655B2 (fr)
EP (1) EP3104839B1 (fr)
JP (1) JP6275877B2 (fr)
KR (1) KR101822133B1 (fr)
CN (1) CN106163498A (fr)
AP (1) AP2016009350A0 (fr)
AR (1) AR099333A1 (fr)
AU (1) AU2015213569B2 (fr)
CA (1) CA2938388C (fr)
CL (1) CL2016001952A1 (fr)
CU (1) CU24444B1 (fr)
DK (1) DK3104839T3 (fr)
DO (1) DOP2016000198A (fr)
EA (1) EA032200B1 (fr)
EC (1) ECSP16069947A (fr)
IL (1) IL246974B (fr)
MA (1) MA39304B1 (fr)
MX (1) MX357765B (fr)
MY (1) MY182620A (fr)
NZ (1) NZ722830A (fr)
PE (1) PE20161173A1 (fr)
PH (1) PH12016501500B1 (fr)
TW (1) TWI538697B (fr)
UA (1) UA118279C2 (fr)
WO (1) WO2015118512A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150036825A (ko) * 2010-04-13 2015-04-07 나지브 바불 1-메틸-2''-6''-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법
CN112546061B (zh) * 2021-02-25 2021-06-11 中南大学湘雅医院 一种肝素类药物组合物、喷鼻剂及其制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3323389A1 (de) * 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
JPH02207018A (ja) * 1989-02-07 1990-08-16 Kao Corp 皮膚外用剤
DE19536244A1 (de) 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung zur lokalen Applikation
IT1275955B1 (it) 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
JPH10279466A (ja) * 1997-04-07 1998-10-20 Kose Corp 外用剤
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
BRPI0101486B1 (pt) 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
NZ577604A (en) * 2006-11-15 2012-06-29 Arthritis Relief Plus Ltd Topical formulation and uses thereof
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
CA2829241A1 (fr) * 2011-04-01 2012-10-04 University Of Florida Research Foundation, Inc. Formulations thermosensibles, mucoadhesives ou dermoadhesives et ameliorant la penetration pour l'administration topique de produits therapeutiques

Also Published As

Publication number Publication date
NZ722830A (en) 2018-01-26
JP2017505344A (ja) 2017-02-16
EA201691596A1 (ru) 2017-01-30
EA032200B1 (ru) 2019-04-30
IL246974B (en) 2018-07-31
WO2015118512A1 (fr) 2015-08-13
TW201532631A (zh) 2015-09-01
CA2938388A1 (fr) 2015-08-13
EP3104839A1 (fr) 2016-12-21
UA118279C2 (uk) 2018-12-26
CU24444B1 (es) 2019-10-04
MX357765B (es) 2018-07-23
AP2016009350A0 (en) 2016-07-31
EP3104839B1 (fr) 2019-11-13
KR20160117529A (ko) 2016-10-10
TWI538697B (zh) 2016-06-21
JP6275877B2 (ja) 2018-02-07
AU2015213569A1 (en) 2016-08-18
MY182620A (en) 2021-01-27
PH12016501500A1 (en) 2017-02-06
US20170165291A1 (en) 2017-06-15
KR101822133B1 (ko) 2018-01-25
MX2016010399A (es) 2017-02-23
AR099333A1 (es) 2016-07-13
PE20161173A1 (es) 2016-10-27
PH12016501500B1 (en) 2017-02-06
CA2938388C (fr) 2018-07-17
MA39304A1 (fr) 2018-01-31
DOP2016000198A (es) 2016-10-31
AU2015213569B2 (en) 2018-01-04
DK3104839T3 (da) 2020-01-20
CN106163498A (zh) 2016-11-23
ECSP16069947A (es) 2018-06-30
CL2016001952A1 (es) 2017-03-10
US9861655B2 (en) 2018-01-09
CU20160119A7 (es) 2016-10-28

Similar Documents

Publication Publication Date Title
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2019001877A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
IL260462B1 (en) Gel preparations for administering a drug through the skin to maximize drug concentrations in the rough layer and serum and methods of using them
CU20180125A7 (es) Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-alpirimidin-3-il)-3 hidroxipirrolidina-1-carboxamida
EA200901112A1 (ru) Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу
MX375222B (es) Compuestos y su uso para reducir los niveles de ácido úrico
EP3305301A4 (fr) Agent thérapeutique contre la sécheresse oculaire caractérisé par sa capacité à être instillé sous forme de goutte dans l'oeil de patients souffrant d'une sécheresse oculaire et portant des lentilles de contact souples
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39304A1 (fr) Formulations topiques d'héparine
BR112018068960A2 (pt) formulações de enalapril
EP3412287A4 (fr) Application de zl-n-91, inhibiteur de phosphodiestérase 4, dans la préparation de médicaments pour la prolifération et les métastases des cellules cancéreuses du poumon
CO2018010568A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2- (etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2- metilpentanoico cristalino, y sus usos
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.
EP3826626A4 (fr) Utilisation d'un conjugué anticorps-médicament anti-cd137 dans une thérapie cellulaire allogénique
EP4122463A4 (fr) Agent médicamenteux sous forme de complexe de 3,3'diindolylméthane et de ?-cyclodextrine
EA201491652A1 (ru) Средство для лечения вирусного гепатита с
EA202090298A1 (ru) Способы лечения муковисцидоза
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов